<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04932863</url>
  </required_header>
  <id_info>
    <org_study_id>35UCS2021</org_study_id>
    <nct_id>NCT04932863</nct_id>
  </id_info>
  <brief_title>BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment</brief_title>
  <acronym>UNICO</acronym>
  <official_title>A Prospective Observational Non Interventional Study of Reactogenicity and Safety of the BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ente Ospedaliero Ospedali Galliera</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Genoa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ente Ospedaliero Ospedali Galliera</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this Italian observational study the antibody titer reactogenicity to Pfizer Severe Acute&#xD;
      Respiratory Syndrome (SARS) - Coronavirus (CoV-2) RNA vaccine in cancer patients under active&#xD;
      antitumor treatment will be evaluated at 21 and 42 days and after 6 months. Furthermore&#xD;
      patients safety will be monitored. Factors affecting immunogenicity (or lack of), including&#xD;
      cancer treatment, will be the primary aim of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational non-interventional study in cancer patients. The study will evaluate&#xD;
      the safety, tolerability and immunogenicity of Pfizer SARS-CoV-2 RNA vaccine against&#xD;
      COronaVIrus Disease-19 (COVID-19) which will be delivered in the deltoid muscle in 2-dose&#xD;
      (separated by 21 days). Blood will be collected in two 5 milliliters (mL) vacuettes for serum&#xD;
      Immunoglobulin G (IgG) and Cytokine assessment, at baseline and after 21 days, immediately&#xD;
      before the first and the second dose, respectively, then after 42 days from the first dose&#xD;
      and finally after 6 months from the baseline. A panel of 22 cytokines (Biorad) will be&#xD;
      measured at baseline and after 21 and 42 days in four groups consisting of: no responders&#xD;
      (S1/S2 IgG&lt;15 Arbitrary Unit AU/ml at 42 days), slow responders (S1/S2 IgG&lt;15 AU/mL after 21&#xD;
      days and &gt;15 AU/mL after the second dose), fast responders (S1/S2 IgG&gt;15 AU/mL after the&#xD;
      first 21 days) and immunized patients (S1/S2 IgG&gt;15 AU/mL at baseline). At baseline, at 42&#xD;
      days and 6 months questionnaires for psychological testing will be dispensed for completion&#xD;
      to patients.&#xD;
&#xD;
      After 42 days from the first dose, 15 mL of heparinized peripheral blood from both&#xD;
      non-responders (S1/S2 IgG&lt;25 AU/mL) and responders will be used for isolation of different&#xD;
      Cluster of Differentiation 4 (CD4+) and CD8+ T cell subpopulations and analysis of their&#xD;
      capability to undergo activation/proliferation in response to specific SARS- CoV-2 derived&#xD;
      peptides.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">March 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody titer reactogenicity assessment</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Serum IgG assessment at baseline, after 21 days, 42 days and after 6 months to Pfizer SARS- CoV-2 RNA vaccine in cancer patients under prior or current active antitumor treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the immune response in treated and untreated patients</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Identification of predictive factors for antibody response in treated versus untreated patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Number and Grade of Adverse Events (AE) related to vaccine in patients undergoing anti-cancer treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titer correlations with therapy</measure>
    <time_frame>up to 24 months</time_frame>
    <description>To correlate the antibody titer with type and timing of therapy. Particular attention will be devoted to the effect in patients receiving checkpoint inhibitor immunotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titer correlations with cancer</measure>
    <time_frame>up to 24 months</time_frame>
    <description>To correlate the antibody titer with the type of cancer and cancer staging/grading</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titer correlations with patients</measure>
    <time_frame>up to 24 months</time_frame>
    <description>To correlate the antibody titer with host characteristics, including psychological variables such as distress and anxiety or depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory response evaluation</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Dosage of soluble factors (including pro-inflammatory cytokines, Cytokine Multiplex Assay Kits) in responders and non responders to Pfizer SARS-CoV-2 RNA vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune cell activation</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Correlate soluble factors of inflammatory response with blood cell count and inflammatory and pro-thrombotic biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological memory</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Comparing lymphocyte activation in cancer patients responding to the vaccine versus those non responding (S1/S2 IgG &lt;15 AU/mL)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Neoplasms</condition>
  <condition>Cancer, Treatment-Related</condition>
  <arm_group>
    <arm_group_label>Subjects with cancer of any type and stage under active or prior medical treatment</arm_group_label>
    <description>BNT162b2 mRNA Covid-19 Vaccine as two injections, 21 days apart, of 30 μg per dose in the deltoid muscle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BNT162b2 mRNA Covid-19 Vaccine</intervention_name>
    <description>Two injections, 21 days apart, of the BNT162b2 vaccine 30 μg per dose in the deltoid muscle.</description>
    <arm_group_label>Subjects with cancer of any type and stage under active or prior medical treatment</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Lymphocytes B and T cells for antigen-specific immune response studies; serum for cytokine&#xD;
      panel&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer patients on current or prior active treatment or ultravulnerable according to&#xD;
        clinical characteristics&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  On treatment for cancer during the last 6 months or being treated &gt;6 months ago but&#xD;
             being ultravulnerable&#xD;
&#xD;
          -  About to receive &quot;Pfizer-BioNTech COVID-19&quot; vaccine&#xD;
&#xD;
          -  Lymphocyte count≥0.5x10^9/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are not eligible for &quot;Pfizer-BioNTech COVID-19&quot; vaccine administration&#xD;
&#xD;
          -  Inability and/or unwillingness to sign written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea De Censi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>E.O. Ospedali Galliera</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco Musso, PhD</last_name>
    <phone>00390105634521</phone>
    <email>marco.musso@galliera.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicoletta Provinciali, MD</last_name>
    <phone>00390105634212</phone>
    <email>n.provinciali@galliera.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>E.O. Ospedali Galliera</name>
      <address>
        <city>Genova</city>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea De Censi, MD</last_name>
      <phone>00390105634501</phone>
      <email>andrea.decensi@galliera.it</email>
    </contact>
    <contact_backup>
      <last_name>Nicoletta Provinciali, MD</last_name>
      <phone>00390105634212</phone>
      <email>n.provinciali@galliera.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ente Ospedaliero Ospedali Galliera</investigator_affiliation>
    <investigator_full_name>Andrea DeCensi</investigator_full_name>
    <investigator_title>Director of Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>neoplasms</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Pfizer SARS- CoV-2 RNA vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in the primary publication of the trial will be shared (text, tables, figures, and appendices), after deidentification</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data will be shared 3 months following the publication of the article and they will remain available for 36 months.</ipd_time_frame>
    <ipd_access_criteria>the investigators who would like to use the data have to prepare a proposal that should be send to the Principal investigator (andrea.decensi@galliera.it).To gain access, data requestors will need to sign a data access agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

